CINECA IRIS Institutional Research Information System

CHIO', Adriano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 28.965
EU - Europa 25.795
AS - Asia 12.851
SA - Sud America 1.747
OC - Oceania 517
AF - Africa 213
Continente sconosciuto - Info sul continente non disponibili 40
Totale 70.128
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.462
IT - Italia 7.397
CN - Cina 5.849
DE - Germania 2.407
IE - Irlanda 2.378
FR - Francia 2.129
GB - Regno Unito 2.048
SG - Singapore 1.831
SE - Svezia 1.541
ES - Italia 1.539
KR - Corea 1.227
FI - Finlandia 1.217
JP - Giappone 1.166
CA - Canada 1.024
BR - Brasile 911
UA - Ucraina 905
NL - Olanda 737
AT - Austria 648
PL - Polonia 592
IN - India 575
VN - Vietnam 516
AU - Australia 463
MX - Messico 395
TR - Turchia 395
BE - Belgio 368
PT - Portogallo 319
RU - Federazione Russa 254
CO - Colombia 238
CH - Svizzera 237
GR - Grecia 237
ID - Indonesia 234
TW - Taiwan 230
HK - Hong Kong 228
CL - Cile 227
AR - Argentina 168
RO - Romania 151
DK - Danimarca 149
IL - Israele 147
HR - Croazia 89
PE - Perù 89
HU - Ungheria 85
NO - Norvegia 69
UZ - Uzbekistan 68
EC - Ecuador 64
CZ - Repubblica Ceca 62
IR - Iran 60
NZ - Nuova Zelanda 54
EG - Egitto 46
PH - Filippine 44
BG - Bulgaria 40
TH - Thailandia 40
EU - Europa 35
BY - Bielorussia 31
PK - Pakistan 31
SN - Senegal 29
TN - Tunisia 29
SA - Arabia Saudita 28
UY - Uruguay 28
MY - Malesia 26
RS - Serbia 26
SI - Slovenia 25
ZA - Sudafrica 24
LB - Libano 21
KZ - Kazakistan 20
CR - Costa Rica 19
MA - Marocco 19
AE - Emirati Arabi Uniti 17
CY - Cipro 17
EE - Estonia 17
LT - Lituania 15
PA - Panama 15
SK - Slovacchia (Repubblica Slovacca) 15
GT - Guatemala 14
IQ - Iraq 14
AL - Albania 12
CU - Cuba 12
BD - Bangladesh 11
LU - Lussemburgo 11
BA - Bosnia-Erzegovina 10
MU - Mauritius 9
NG - Nigeria 9
SC - Seychelles 9
TJ - Tagikistan 9
VE - Venezuela 9
BO - Bolivia 8
NP - Nepal 8
PS - Palestinian Territory 8
CI - Costa d'Avorio 7
IS - Islanda 7
KE - Kenya 7
MT - Malta 7
DO - Repubblica Dominicana 6
QA - Qatar 6
DZ - Algeria 5
FO - Isole Faroe 5
LV - Lettonia 5
MK - Macedonia 5
PY - Paraguay 5
GE - Georgia 4
ML - Mali 4
Totale 70.062
Salva come PNG Salva come JPEG
Città #
Beijing 2.734
Chandler 2.469
Dublin 2.269
Houston 1.561
Singapore 1.402
Fairfield 1.191
Santa Clara 1.152
Ashburn 1.124
Torino 985
Redwood City 881
Jacksonville 812
Villeurbanne 805
Wilmington 750
Princeton 704
Ann Arbor 665
Woodbridge 665
Medford 628
Milan 595
Columbus 584
Vienna 558
Seattle 549
Cambridge 470
Warsaw 465
Turin 399
Nyköping 397
Dearborn 368
Rome 353
Dong Ket 343
Boston 323
Pisa 309
Toronto 301
Tokyo 285
Shanghai 260
Guangzhou 250
Fremont 248
Lappeenranta 241
London 220
Chengdu 215
New York 213
Boardman 206
Hangzhou 206
Nanjing 185
Jakarta 177
Paris 172
Los Angeles 164
Madrid 164
Taipei 158
Santiago 136
Munich 131
Barcelona 130
Utrecht 125
Ottawa 122
San Diego 122
Chicago 121
Verona 114
Helsinki 108
Brussels 100
Bogotá 97
Sydney 95
São Paulo 94
Athens 92
Stockholm 92
Washington 91
Changsha 89
Bologna 88
Istanbul 88
Sanayi 88
Amsterdam 86
Valencia 86
Wuhan 86
Norwalk 84
Hefei 77
Mumbai 77
Buenos Aires 76
Seoul 75
Padova 73
Berlin 72
Duncan 71
Lisbon 70
Florence 69
Lima 67
Zhengzhou 66
Detroit 64
Mountain View 64
Falls Church 63
Hong Kong 63
Melbourne 63
Philadelphia 63
San Francisco 63
Fuzhou 62
Brisbane 59
Murcia 59
Hebei 58
Atlanta 57
Oxford 54
Phoenix 54
Hanover 53
Jinan 53
Montreal 53
Budapest 52
Totale 34.490
Salva come PNG Salva come JPEG
Nome #
Amyotrophic lateral sclerosis 7.667
Amyotrophic lateral sclerosis: moving towards a new classification system 3.264
Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model 3.234
Disease-modifying therapies in amyotrophic lateral sclerosis 1.765
Specialist palliative care improves the quality of life in advanced neurodegenerative disorders: NE-PAL, a pilot randomised controlled study 1.517
State of play in amyotrophic lateral sclerosis genetics 1.221
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial 1.215
The changing picture of amyotrophic lateral sclerosis: lessons from European registers 959
Il Bergamini di Neurologia 780
Amyotrophic lateral sclerosis and food intake 763
Pain in amyotrophic lateral sclerosis 755
Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study 626
A20 in Multiple Sclerosis and Parkinson’s Disease: Clue to a Common Dysregulation of Anti-Inflammatory Pathways? 521
Intraspinal stem cell transplantation for amyotrophic lateral sclerosis: Ready for efficacy clinical trials? 519
Network Analysis Identifies Disease-Specific Pathways for Parkinson’s Disease 504
Clinical phenotypes and radiological findings in frontotemporal dementia related to TARDBP mutations 487
Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis 483
null 439
A Multicentric Prospective Incidence Study of Guillain-Barre Syndrome in Italy. the ITANG Study 434
Incidence of amyotrophic lateral sclerosis in the province of Novara, Italy, and possible role of environmental pollution 405
C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinson’s disease complicated by psychosis or dementia in a Sardinian population 398
The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. 390
The MITOS system predicts long-term survival in amyotrophic lateral sclerosis 365
MRI signatures of the frontotemporal lobar degeneration continuum 339
NADPH oxidase 2 (NOX2) enzyme activation in patients with chronic inflammatory demyelinating polyneuropathy 330
Percorso diagnostico terapeutico assistenziale dell'epilessia. 313
Acoustic reflex patterns in amyotrophic lateral sclerosis 306
Decreased Levels of Foldase and Chaperone Proteins Are Associated with an Early-Onset Amyotrophic Lateral Sclerosis 292
Influence of frontotemporal dementia in ALS patients and caregivers quality of life and depression 287
July 2017 ENCALS statement on edaravone 286
Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial 282
Validation of the Italian version of self-administered ALSFRS-R scale 274
Validation of the revised classification of cognitive and behavioural impairment in ALS 269
Curable or treatable? The implications of different definitions of illness when treating patients affected by Amyotrophic Lateral Sclerosis 245
ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry 239
The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease 237
Coffee and Amyotrophic Lateral Sclerosis: A Possible Preventive Role 232
Amyotrophic Lateral Sclerosis Incidence and Previous Prescriptions of Drugs for the Nervous System 223
Acute, Hemorrhagic, Necrotizing Pancreatitis Associated With Riluzole Treatment in a Patient With Amyotrophic Lateral Sclerosis 222
The role of arterial blood gas analysis (ABG) in amyotrophic lateral sclerosis respiratory monitoring 221
Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. 217
Projected increase in amyotrophic lateral sclerosis from 2015 to 2040 216
Genome-wide Analyses Identify KIF5A as a Novel ALS Gene 216
G-quadruplex-binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo 204
ATXN2 polyQ intermediate repeats are a modifier of ALS survival. 198
18 F-FDG-PET correlates of cognitive impairment in ALS 197
A genome-wide association study of myasthenia gravis 196
Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels. 195
Factors predicting survival in ALS: a multicenter Italian study 189
CHCH10 mutations in an Italian cohort of familial and sporadic amyotrophic lateral sclerosis patients 188
SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis 183
Genetic correlation between amyotrophic lateral sclerosis and schizophrenia 179
Amyotrophic lateral sclerosis onset after prolonged treatment with a VEGF receptors inhibitor. 175
A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis 174
Alcohol and amyotrophic lateral sclerosis: A possible neuroprotective effect 170
Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD 168
A longitudinal study on quality of life and depression in ALS patient-caregiver couples 164
The multistep hypothesis of ALS revisited: The role of genetic mutations 160
Age-related penetrance of the C9orf72 repeat expansion 159
Use of genetic testing in amyotrophic lateral sclerosis by neurologists 159
NOX2 in the hSOD1G93A Transgenic Swine: a preliminary overview 158
ATNX2 is not a regulatory gene in Italian amyotrophic lateral sclerosis patients with C9ORF72 GGGGCC expansion 158
Secular trends of amyotrophic lateral sclerosis: The Piemonte and Valle d’Aosta register 158
La continuità assistenziale: miraggio o possibilità? 158
C9ORF72 hexanucleotide repeat exerts toxicity in a stable, inducible motor neuronal cell model, which is rescued by partial depletion of Pten 154
A novel p.Ser108LeufsTer15 SOD1 mutation leading to the formation of a premature stop codon in an apparently sporadic ALS patient: insights into the underlying pathomechanisms 151
Erythropoietin in amyotrophic lateral sclerosis: A multicentre, randomised, double blind, placebo controlled, phase III study 148
ALS mutant FUS proteins are recruited into stress granules in induced pluripotent stem cell-derived motoneurons 148
Diffusion Tensor and Voxel Based Morphometry study in patients with amyotrophic lateral sclerosis 146
Proteostasis and ALS: Protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS) 146
What is the role of the placebo effect for pain relief in neurorehabilitation? Clinical implications from the Italian consensus conference on pain in neurorehabilitation 145
Risk factors in the early diagnosis of ALS: European epidemiological studies. 143
Does Recognition of Facial Expression of Primary and Social Emotions in ASL Patients Interfere with Social Competence? 142
No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis 142
Correlation between Apolipoprotein E genotype and brain metabolism in amyotrophic lateral sclerosis 142
Large Proportion of Amyotrophic Lateral Sclerosis Cases in Sardinia Due to a Single Founder Mutation of the TARDBP Gene 141
Influence of cigarette smoking on ALS outcome: A population-based study 138
A Strange Loop: Effects of emotional facial expressions impaired recognition in ALS Patients and in their Caregivers. 137
Constructional apraxia in frontotemporal dementia associated with the C9orf72 mutation: Broadening the clinical and neuropsychological phenotype. 136
Mutations in the CHCHD10 gene are a common cause of familial amyotrophic lateral sclerosis. 136
Spatial epidemiology of Amyotrophic Lateral Sclerosis in Piedmont and Aosta Valley, Italy: a population-based cluster analysis 136
The Present and the Future of Neuroimaging in Amyotrophic Lateral Sclerosis 132
Can eye-tracking system communication improve quality of life and mood in ALS patients with locked-in syndrome 132
Assessing and treating pain in movement disorders, amyotrophic lateral sclerosis, severe acquired brain injury, disorders of consciousness, dementia, oncology and neuroinfectivology. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation 130
A Distinct MR Imaging Phenotype in Amyotrophic Lateral Sclerosis: Correlation between T1 Magnetization Transfer Contrast Hyperintensity along the Corticospinal Tract and Diffusion Tensor Imaging Analysis. 128
Expression of NOX2 protein in neutrophils of patients with ALS 125
Serum C-reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis 125
Persistent idiopathic hypoglossal nerve palsy: A motor neuron disease-mimic syndrome? 124
Increased cytoplasmic mislocalization of TAR DNA binding protein 43 (TDP-43) in circulating lymphomonocytes of ALS patients recapitulates the major dysfunction featuring motor neurons in the disease. 123
Increased risk of ALS for frontline workers 123
Non-self-sufficiency as a primary outcome measure in ALS trials 122
Multicenter validation of [18F]-FDG PET and support-vector machine discriminant analysis in automatically classifying patients with amyotrophic lateral sclerosis versus controls 120
Cognitive impairment across ALS clinical stages in a population-based cohort 118
Amyotrophic lateral sclerosis, physical exercise, trauma and sports: results of a population-based pilot case-control study 117
G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial) 115
Genetic counselling in ALS: facts, uncertainties and clinical suggestions 115
Tumor cell proliferation and apoptosis in medulloblastoma 113
NADPH Oxidases (NOX) Enzymes Induced Oxidative Stress in CIDP Patients 113
Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis 111
Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial) 111
Totale 42.375
Salva come PNG Salva come JPEG
Categoria #
all - tutte 179.276
article - articoli 0
book - libri 0
conference - conferenze 25.945
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 205.221
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.901 0 0 0 0 0 1.354 890 634 939 916 643 525
2020/20218.978 735 563 618 560 833 629 733 511 1.154 903 651 1.088
2021/20228.950 484 459 570 778 618 633 654 583 559 712 1.325 1.575
2022/202311.689 1.208 775 405 952 1.118 2.397 985 793 1.224 545 712 575
2023/20248.778 865 1.008 585 669 689 714 590 899 224 847 752 936
2024/20256.892 503 1.124 824 1.531 2.503 407 0 0 0 0 0 0
Totale 72.194